Stephen Buhner's Japanese Knotweed Protocol for Lyme

Background & Cultural Context

Stephen Harrod Buhner (1952-2022) was a clinical herbalist whose book Healing Lyme (first published 2005, second edition 2015) remains one of the most-cited integrative references for chronic tick-borne illness. The protocol centers on Polygonum cuspidatum (Japanese knotweed) root, which contains resveratrol, emodin, and a family of related stilbenes and anthraquinones. Buhner specified standardized whole-root tincture rather than isolated resveratrol supplements because the synergistic chemistry of the whole-root extract is what allows the active compounds to cross the blood-brain barrier and reach the central-nervous-system tissues where Borrelia burgdorferi spirochetes preferentially concentrate.

Knotweed itself is not a traditional Western herb. It originated in East Asia, where it has a long history in Japanese kampo and Chinese medicine under the name hu zhang, used for jaundice, amenorrhea, and traumatic injury. It arrived in North America in the late nineteenth century as an ornamental and quickly escaped cultivation. The plant is now considered one of the most aggressive invasive species in the temperate world. That fact shapes the protocol's sourcing ethics: knotweed roots can be harvested wild from naturalized stands in the northeastern United States, Britain, and Central Europe without depleting any native population. In several jurisdictions removal is actively encouraged or legally mandated.

Buhner did not present knotweed as a stand-alone treatment. He described a core triad: knotweed for systemic anti-spirochete and neuroprotective effect, cat's claw (Uncaria tomentosa) for immune modulation and joint inflammation, and andrographis (Andrographis paniculata) for acute Borrelia load reduction. Around that triad he sequenced additional herbs depending on which coinfections — Babesia, Bartonella, Ehrlichia, Mycoplasma — a clinician had identified. The book is explicit that the protocol assumes a Lyme-literate clinician is involved; it is not a self-treatment guide for someone bypassing medical care.

The herbal community around Buhner's work has continued after his death. Established Appalachian and Pacific Northwest herbalists keep the dose and sourcing notes current, and the protocol is taught in clinical herbalism programs in the United States and the United Kingdom. The 2015 second edition incorporated several refinements from a decade of clinical feedback: a lower starting dose for highly sensitive patients, a longer titration period for those with neurological presentation, and revised guidance on combining the protocol with intravenous or oral antibiotics during the acute treatment window.

The plant's ethnobotanical history beyond its medicinal use is also relevant. Young knotweed shoots are edible — they taste like sour rhubarb when sauteed or stewed — and are commercially foraged in Japan, Korea, and increasingly in the northeastern United States. That edibility carries centuries of safety evidence: the plant has been eaten by millions of people across multiple cultures without recorded harm at culinary doses. Tincture doses are higher than dietary intake, but the underlying safety profile is what gives clinicians confidence to use the herb in long-treatment regimens. The same logic explains why the protocol relies on whole-root tincture rather than isolated resveratrol — the whole-plant safety record does not automatically transfer to a purified single compound at much higher concentration.

Modern Application

The published baseline dose is one teaspoon of standardized Japanese knotweed root tincture taken three to six times daily, adjusted upward in stages as tolerated. Buhner specified tinctures prepared from fresh or freshly dried root rather than older dried material, because stilbene content degrades on the shelf. The accompanying cat's claw and andrographis tinctures are dosed independently — typically one to two teaspoons three times daily for cat's claw and one-half teaspoon three times daily for andrographis, with the andrographis cycled (two weeks on, one week off) because it can be hepatotoxic at sustained high doses.

Suppliers used by clinicians who teach the protocol include Woodland Essence in upstate New York and Green Dragon Botanicals in Vermont, both of whom publish their sourcing and extraction methods. Patients are advised to start at one-quarter the target dose for the first week to surface any Herxheimer-type response (transient inflammation as bacterial die-off spikes cytokines) and to taper upward over two to three weeks.

A complete clinical course typically runs four to eighteen months. Acute and early-disseminated Lyme cases generally respond within twelve to sixteen weeks. Late-stage or chronic presentations require longer courses, periodic dose holidays, and reassessment with a Lyme-literate clinician every three months. The protocol pairs well with the conventional doxycycline or amoxicillin regimens that follow ILADS guidance; many treating clinicians use the herbs alongside the antibiotic course and continue them after the antibiotic completes as anti-inflammatory and neuroprotective maintenance.

Honest limits: the protocol is documented through clinical case series and Buhner's own thirty-year practice, not large randomized trials. Resveratrol's antibacterial activity against Borrelia in vitro is documented (Goc and Rath, 2016, in the Journal of Applied Microbiology), but in vitro activity does not automatically translate to in vivo cure. The protocol is intended as an adjunct to conventional medical care, never as a replacement. Anyone with suspected or confirmed Lyme disease should consult a clinician familiar with the ILADS treatment guidelines and verify any herb-drug interaction (knotweed has anticoagulant activity that compounds warfarin, and andrographis can affect cyclosporine metabolism). The protocol is not appropriate during pregnancy because andrographis has documented uterine-stimulant effects at therapeutic doses.